Mercury Laboratories Limited (BOM:538964)

India flag India · Delayed Price · Currency is INR
749.60
-20.35 (-2.64%)
At close: Apr 28, 2026
-8.08%
Market Cap 894.00M
Revenue (ttm) 761.53M
Net Income (ttm) 47.19M
Shares Out 1.20M
EPS (ttm) 39.31
PE Ratio 18.95
Forward PE n/a
Dividend 3.50 (0.47%)
Ex-Dividend Date Aug 6, 2025
Volume 56
Average Volume 85
Open 785.95
Previous Close 769.95
Day's Range 727.00 - 785.95
52-Week Range 620.55 - 976.00
Beta 0.44
RSI 46.34
Earnings Date May 8, 2026

About Mercury Laboratories

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergi... [Read more]

Industry Pharmaceutical Preparations
Founded 1962
Employees 503
Stock Exchange Bombay Stock Exchange
Ticker Symbol 538964
Full Company Profile

Financial Performance

In fiscal year 2025, Mercury Laboratories's revenue was 751.01 million, a decrease of -0.61% compared to the previous year's 755.59 million. Earnings were 31.45 million, a decrease of -44.38%.

Financial Statements

News

There is no news available yet.